Citation:Hu XN, Ni Y, Luan J, Ding YZ. A review on vasohibin and ocular neovascularization. Int J Ophthalmol 2020;13(6):1004-1008,doi:10.18240/ijo.2020.06.22
A review on vasohibin and ocular neovascularization
Received:August 30, 2019  Revised:October 16, 2019
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2020.06.22
Key Words:vasohibin  ocular neovascularization  retinal neovascularization
Fund Project:Supported by Natural Science Fund Project in Jiangsu Province (No.BK20180380); Nanjing Health Commission (No.YKK18260).
           
AuthorInstitution
Xiao-Nan Hu Department of Ophthalmology, Zhongda Hospital Southeast University, Nanjing , Jiangsu Province, China; Medical School of Southeast University, Nanjing , Jiangsu Province, China
Yan Ni Department of Ophthalmology, Zhongda Hospital Southeast University, Nanjing , Jiangsu Province, China
Jie Luan Department of Ophthalmology, Zhongda Hospital Southeast University, Nanjing , Jiangsu Province, China
Yu-Zhi Ding Department of Ophthalmology, Zhongda Hospital Southeast University, Nanjing , Jiangsu Province, China
Hits: 100
Download times: 21
Abstract:
      Ischemic and neovascular disease is one of the most difficult ocular diseases to deal with nowadays. Redundancy, poor visual acuity and decreased life quality are bothering patients and ophthalmologists for decades. After vascular endothelial growth factor (VEGF) was found to be a primary factor in promoting retinal angiogenesis, intravitreal injection of anti-VEGF drugs has been the first-line treatment. Whereas, some patients are refractory to this therapy and problems of economic burden, local complications and adverse effects promote researches into other possible targets. The vasohibin (VASH) family is a newly-investigated factor in modulating ocular angiogenesis. The family includes VASH1 and VASH2, which show opposite effects of inhibiting and accelerating angiogenesis respectively. Positive results have been reported in cellular and animal experiments. With further researches, it can be a promising future target of treating ocular neovascular diseases.
PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270253/
Supplementary Material
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment